Profile

Biography

Eldon is a Research Fellow based in the Team for Economic Evaluation and Health Technology Assessment.  He joined the Centre for Health Economics in 2010.  He holds a BA (2002) and MA (2006) in Economics from the University of Calgary and a PhD (2009) from the Pharmaceutical Outcomes and Policy Program at the University of Washington.  His research interests include the use of decision-analytic models and the characterization and effect of uncertainty.  He has worked in diverse disease areas including: asthma, metabolic syndrome, hepatitis B, epilepsy, psoriasis, rheumatoid arthritis, osteoporosis and ulcerative colitis, with a recent focus in Alzheimer disease. 

Research

Overview

• Appropriate use of 'only in research' coverage decisions
• Cost-effectiveness of diagnostics and screening
• Health and economic measures of Alzheimer disease
• Patient level simulation in health economic models
• Characterizing uncertainty

Research group(s)

• Economic evaluation of health technologies
  

Publications

Full publications list

2013

• Blickem C, Blakeman T, Kennedy A, Bower P, Reeves D, Gardner C, Lee V, Chew-Graham C, Richardson G, Brooks H, Dawson, S, Mossabir R, Jariwala, P, Swallow A, Kontopantelis E, Gaffney H, Small N, Spackman E, Rogers A. The clinical and cost-effectiveness of the BRinging Information and Guided Help Together (BRIGHT) intervention for the self-management support of people with stage 3 chronic kidney disease in primary care: study protocol for a randomized controlled trial. Trials 2013;14(1):28.
• Claxton K, Martin S, Soares M, Rice N, Spackman E, Hinde S, Devlin N, Smith PC, Sculpher M. Methods for the estimation of the NICE cost effectiveness threshold. Centre for Health Economics, University of York, CHE Research Paper 81 (PDF , 3,944kb)‌ 2013.
• Howard J, Malfroy M, Llewelyn C, Choo L, Hodge R, Johnson T, Purohit S, Rees D, Tillyer L, Walker I, Fijnvandraat K, Kirby-Allen M, Spackman E, Davies S, Williamson L.  The transfusion alternatives preoperatively in sickle cell disease (TAPS) study: a randomised controlled multi-centre clinical trial. The Lancet 2013;381(9870):930-938.
• Longworth L, Youn J, Bojke L, Palmer S, Griffin S, Spackman E, Claxton, K. When does NICE recommend the use of Health technologies within a programme of evidence development?:A systematic review of NICE guidance. Pharmacoeconomics  2013;31(2):137-49.
• Naci H, Spackman E. National approaches to comparative effectiveness research. In: Handbook of Health Services Research. Springer  2013.
• Spackman E, Kadiyala S, Neumann PJ, Veenstra DL, Sullivan SD. The validity of dependence as a health outcome measure in Alzheimer disease.  American Journal of Alzheimer's Disease & Other Dementias 2013;doi:10.1177/1533317513481092.
• Spackman E, Rice S, Norman G, Suh D-C, Eastwood A, Palmer S. Trastuzumab for the treatment
  of HER2-positive metastatic gastric cancer: A NICE single technology appraisal.
  Pharmacoeconomics 2013; 31(3):185-194.

2012

• Bojke L, Spackman E, Hinde S, Helliwell P. Capturing all of the costs in NICE appraisals: the impact of inflammatory rheumatic diseases on productivity. Rheumatology 2012;51(2):210-215
• Claxton K, Palmer S, Longworth L, Bojke L, Griffin S, McKenna C, Soares M, Spackman DE, Youn J. Informing a decision framework for when NICE should recommend the use of health technologies only in the context of an appropriately designed programme of evidence development. Health Technology Assessment 2012;16. Download from hta
• Spackman DE, Kadiyala S, Neumann PJ, Veenstra DL, Sullivan SD. Measuring alzheimer disease progression with transition probabilities: estimates from NACC-UDS. Current Alzheimer Research 2012;9(9):1050-58. 

2011

• Bloudek LM, Spackman DE, Blankenburg M, Sullivan SD. Review and meta-analysis of biomarkers and diagnostic imaging in alzheimer's disease. J Alzheimers Dis 2011;26(4).
• Bloudek LM, Spackman DE, Veenstra DL, Sullivan SD. CDR state transition probabilities in alzheimer's disease with and without cholinesterase inhibitor intervention in an observation cohort J Alzheimers Dis 2011;24(3)Feb.
• Claxton K, Palmer S, Longworth L, Bojke L, Griffin S, McKenna C, Soares M, Spackman DE, Youn J. Uncertainty, evidence and irrecoverable costs: Informing approval, pricing and research decisions for health technologies. Centre for Health Economics, University of York; CHE Research Paper 69 (PDF , 1,860kb)‌‎ 2011.
• Norman G, Rice S, Spackman E, Stirk L, Danso-Appiah A, Suh D, Palmer S, Eastwood A. Trastuzumab for the treatment of HER2 positive metastatic adenocarcinoma of the stomach or gastro-oesophageal junction. Health Technol Assess 2011;15(Suppl 1):33-42.

2010

• Bloudek L, Spackman DE, Sullivan SD. A comparison of transitions between health states and institutionalization among alzheimer's disease patients versus non-alzheimer's disease dementia patients using the nacc-uds database. Value in Health 2010;13(3):108-9.
• Campbell JD, Spackman DE. The costs and consequences of Omalizumab in uncontrolled Asthma from a USA payer perspective. Allergy 2010;65(9):1141-48.
• Fleurence R, Spackman DE, Hollenbeak CS. Does the funding source influence the results in economic evaluations?  A case study in bisphosphonates for the treatment of osteoporosis. Pharmacoeconomics 2010;28(4):295-306.
• McLaughlin T, Feldman H, Fillit H, Sano M, Schmitt F, Aisen P, Leibman C, Mucha L, Ryan JM, Sullivan SD, Spackman DE, Neumann PJ, Cohen J, Stern Y. Dependence as a unifying construct in defining Alzheimer disease severity. Alzheimer's & Dementia 2010;6(6):482-03.

2008

• Campbell JD, Spackman DE, Sullivan SD. Health economics of asthma: assessing the value of asthma interventions. Allergy. 2008 Dec;63(12):1581-92.
• Spackman DE, Veenstra DL. A cost-effectiveness analysis of currently approved treatments for HBeAg-positive chronic hepatitis B. Pharmacoeconomics. 2008;26(11):937-49.
• Veenstra DL, Spackman DE, Di Bisceglie A, Kowdley KV, Gish RG. Evaluating anti-viral drug selection and treatment duration in HBeAg-negative chronic hepatitis B: a cost-effectiveness analysis. Aliment Pharmacol Ther. 2008 Jun;27(12):1240-52.

2007

• Spackman DE, Yeates A, Rentz AM, Hutton J. The cost effectiveness of zonisamide as adjunctive therapy in adult partial seizure epilepsy. J Med Econ 2007;10(4): 455-473.
• Campbell JD, Spackman DE, Sullivan SD. Revisiting the cost-effectiveness of omalizumab. Allergy. 2007 Dec;62(12):1469.
• Caro JJ, O'Brien JA, Hollenbeak CS, Spackman E, Ben-Joseph R, Okamoto LJ, et al. Economic burden and risk of cardiovascular disease and diabetes in patients with different cardiometabolic risk profiles. Value in Health. 2007;10(s1):S12-S20.
• Hollenbeak CS, Spackman DE, Ben-Joseph RH, Okamoto LJ, Luce BR, Schwartz JS, et al. Predicting the prevalence of cardiometabolic risk factors when clinical data are limited. Value in Health. 2007;10(s1):S4-S11.
• Hollingworth W, Spackman DE. Emerging methods in economic modeling of imaging costs and outcomes a short report on discrete event simulation. Acad Radiol. 2007 Apr;14(4):406-10.

2006

• Fleurence R, Spackman E. Cost-effectiveness of biologic agents for treatment of autoimmune disorders: structured review of the literature. J Rheumatol. 2006 Nov;33(11):2124-31.